Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
345
resultados
Última actualización
16/10/2026 [07:35:00]
Resultados 275 a 300 de 345
Resumen de: US20260251655A1
0000 The present invention is directed to methods for determining the level of PAM and/or its isoforms and/or fragments thereof in a bodily fluid or a tissue sample using an assay, wherein said assay is comprising at least one binder that is directed to a conformational epitope of PAM, and its use for diagnostic purpose.
Resumen de: WO2026176371A1
The present disclosure is related to drug delivery compositions containing extracellular vesicles having a therapeutic by utilizing visceral sensory neurons, a method using thereof for delivering the drugs to central nervous system and an organoid on chip model comprising a three-compartment axis-on-a chip for testing delivery of the drug containing EV over BBB, wherein the compositions comprising bacterial extracellular vesicles (EV) and therapeutics, wherein the drug or the therapeutic is encapsulated within the EV or attached or conjugated to EV.
Resumen de: US20260250647A1
0000 The present disclosure relates to a chimeric protein molecule comprising a degradation domain including an E3 ubiquitin ligase motif without lysine residues and a targeting domain comprising a substrate-binding motif which is heterologous to the E3 ubiquitin ligase motif. A linker couples the degradation domain to the targeting domain. Also disclosed are compositions as well as methods of treating a disease, substrate silencing, forming a ribonucleoprotein, screening agents for therapeutic efficacy against a disease, and methods of screening for disease biomarkers, as well as mRNA molecules, vectors, and encapsulated nucleic acid molecules encoding chimeric protein molecules.
Resumen de: US20260251568A1
Disclosed herein is a device for chiral sensing comprising a chiral plasmonic substrate, wherein when the device is assembled together with a first light source, a liquid sample comprising a plurality of chiral analytes, a second light source, and an instrument, the first light source is configured to illuminate the chiral plasmonic substrate with electromagnetic radiation; and the second light source is configured to illuminate the chiral plasmonic substrate with circularly polarized electromagnetic radiation. The instrument is configured to process electromagnetic signal from the first light source and the second light source to determine a property of the liquid sample.
Resumen de: US20260251650A1
0000 The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
Resumen de: US20260251634A1
A method of analyzing neurons includes: identifying a cell region by identifying a region of a neurite or a region of a cell body of a neuron on the basis of time-series images obtained by imaging the neuron in time series; detecting aggregates by imaging, in time series, first fluorescent protein tagged to specific protein expressed in the neuron and detecting presence or absence of aggregates of the specific protein aggregated in the region of the neurite or the region of the cell body identified in the identifying the cell region on the basis of luminance of the first fluorescent protein included in the time-series images; and performing an analysis by classifying the neuron into a plurality of groups on the basis of a detection result of the detecting the aggregates and analyzing a survival state of the neuron for each of the groups.
Resumen de: US20260248877A1
0000 The present invention provides inhibitory peptides for use in the diagnostic and/or treatment of tauopathies, in particular Alzheimer's Disease and Pick's Disease. The inhibitory peptides comprise a hexapeptide sequence that specifically inhibits interactions of the PHF6 sequence within pathological Tau protein.
Resumen de: US20260251557A1
0000 A method includes contacting one or more volatile organic compounds (“VOCs”) evolved from a sample to one or more detection regions configured for sensitivity against one or more VOCs. The contacting causes a change to the detection regions that is visible to the human eye. The method also includes determining the presence or absence of a VOC by comparing the change to the detection regions to a key, with the key being a visible change. A system utilizing the method is also described.
Resumen de: US20260251665A1
0000 A method of aiding diagnosis of a disease or condition in a subject, wherein the method comprises comparing a level of at least one natriuretic peptide detected in a biological sample obtained from the subject with a reference level of the at least one natriuretic peptide, wherein the biological sample is an oral mucosal transudate (OMT) sample obtained from one or more mucous membranes inside the mouth of the subject.
Resumen de: US20260251664A1
0000 The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of dementia in a middle-aged individual within a specified timeframe, for example 5, 10, 15 and/or 20 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of dementia within 5, 10, 15 and/or 20 years. In another aspect, methods are provided for evaluating risk of dementia within 5, 10, 15 and/or 20 years in a middle-aged individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.
Resumen de: WO2026176083A1
The present invention relates to a method for diagnosing a patient having a neurological (including neuromuscular) disorder, such as ALS. The invention further relates to a method for distinguishing between neurological disorders, said method extending to include the ability to discriminate one subtype from other subtypes of the same disorder.
Resumen de: WO2026178110A1
Disclosed is a method for the treatment of major depressive disorder (MDD), which includes administering to a human subject suffering from MDD, a therapeutically effective amount of an antibody selected from fezakinumab, ustekinumab, gusacitinib and dupilumab, and combinations thereof.
Resumen de: WO2026177204A1
The purpose of the present invention is to provide a novel naturally derived cellular vesicle staining agent that can easily fluorescently stain cellular vesicles and that is safe even when introduced into the body, and to provide a cellular vesicle staining agent having anti-inflammatory activity. The purpose of the present invention is also to provide a method for producing a cellular vesicle staining agent, whereby the cellular vesicle staining agent can be easily produced. Another purpose of the present invention is to provide a method for detecting cellular vesicles using the cellular vesicle staining agent. The present invention provides: a cellular vesicle staining agent comprising chlorophyll or a chlorophyll derivative; an anti-inflammatory agent comprising chlorophyll or a chlorophyll derivative as an active ingredient; a method for producing a cellular vesicle staining agent, the method comprising a step for extracting a cellular vesicle staining agent from a photosynthetic organism; and a method for detecting a cellular vesicle in a sample or in a body using the cellular vesicle staining agent.
Resumen de: WO2026175415A1
Disclosed is a preparation technical method capable of preparing a large number of pathogenic tau proteins having a pathological conformation similar to that in the brain of a patient with neurodegenerative diseases by means of in vitro preparation and continuous multi-round amplification. The method can achieve continuous multi-round amplification of a patient brain-derived pathological tau protein by using only a small amount of the patient brain-derived pathological protein as a template, a recombinant human-derived tau protein monomer, and a negatively charged polyanion compound as an inducing cofactor, thereby achieving the in vitro preparation of a large amount of the pathological tau protein. In addition, the pathological tau protein prepared by the method can maintain the special pathological conformation of the original tau protein of the disease, has the same pathological activity as the original tau protein, and can be used for probe screening, antibody preparation, and verification model development.
Resumen de: US20260250375A1
0000 The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
Resumen de: US20260251541A1
0000 The present invention relates to a method of fixing extracellular vesicles. The method includes providing a sample containing extracellular vesicles and contacting the sample with a non-reversible cross-linking agent and, optionally, an aldehyde-containing fixative. Preferably the non-reversible cross-linking agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. The method also includes imaging the fixed extracellular vesicles for the determination or exclusion of disease or disorder in a clinical sample. The present invention also relates to a kit for fixing extracellular vesicles in a biological sample.
Resumen de: US20260251660A1
The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
Resumen de: WO2025081242A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Resumen de: WO2025085755A1
Disclosed are methods of detecting or quantifying a pathology -related or pathology-protective-pathway in a subject comprising combining a first ligand with a sample obtained from the subject comprising an extracellular particle, wherein the first ligand binds to a cell-type specific marker on the extracellular particle; combining a second ligand with the sample, wherein the second ligand binds to a pathology-related or pathology-protective pathway molecule on the extracellular particle; combining a donor bead to the sample, wherein the donor bead binds to the first ligand or second ligand; combining an acceptor bead to the sample, wherein the acceptor bead binds to the first ligand or second ligand, wherein the donor bead and acceptor bead do not bind to the same ligand; triggering the donor bead to activate the acceptor bead to produce a signal; wherein the amount, presence, or absence of a signal indicates the amount, presence, or absence of a pathological condition in the subject.
Resumen de: EP4796928A1
The present disclosure relates to an in vitro method for diagnosing Alzheimer's disease (AD) in a subject, the method comprising a step of determining the level of β-secretase 1 protein (BACE-1) comprised in a population of brain-derived extracellular vesicles (BDEVs) in an isolated sample obtained from the subject, particularly wherein the population of BDEVs carry neuroligin-3 (NLGN3), wherein when the level of BACE-1 is equal to or higher than a reference this is indicative of a positive diagnosis of Alzheimer's disease. Also provided herein are methods of determining the classification of a subject according to the A/T/N system, methods for recommending a medical regimen, methods for determining therapeutic efficacy of a medical regiment, as well as methods of treatment for AD and AD-associated pathologies in a subject. Finally, the present disclosure provides kits and devices comprising: a) means for capturing a population of brain-derived extracellular vesicles; b) means for detecting the presence and/or for determining the level of BACE-1 protein; and optionally, c) a solid support.
Resumen de: EP4796930A2
Disclosed herein are methods of detecting a plurality of targets comprising different nucleic acid sequences or different proteins within an optically resolved volume of a cell in situ.
Resumen de: EP4796929A2
0001 A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.
Resumen de: CN122631731A
0001 本发明公开了表位分子印迹膜库的构建结合场效应晶体管用于检测超灵敏生物检测的方法，用于多种生物分子的检测；同时将制备的表位分子印迹膜库与场效应晶体管技术相结合开发一种高灵敏生物检测的方法，属于生物传感器技术领域；通过在铜箔表面制备分子印迹膜，并且印迹不同的肽段分子从而建立分子印迹膜库；在铜箔刻蚀去除后将膜转移到石墨烯表面构建场效应晶体管，借助石墨烯的高灵敏可以实现不同分子的检测；肽段或蛋白可以进入到分子印迹的特异性空腔中，进而引起电信号的变化，实现生物分子的放大检测；该发明首次实现表位分子印迹膜库的建立，证明了方法的通用性，实现了多种生物样品的高特异性，快速、超敏的检测。
Resumen de: CN122631903A
0001 本发明公开了溶酶体功能轴的神经退行性疾病血液标志物组合及试剂盒，涉及生物医学检测技术领域。该标志物组合由以下三类共7个标志物组成：葡萄糖脑苷脂酶和组织蛋白酶D；鞘脂和神经节苷脂；以及磷酸化tau‑217蛋白、神经丝轻链蛋白和胶质纤维酸性蛋白。本发明还提供了一种体外诊断试剂盒，包含检测上述标志物的特异性试剂，并构建了基于逻辑回归或随机森林算法的风险评估模型。所述标志物组合及试剂盒可用于阿尔茨海默病、帕金森病及神经性戈谢病等神经退行性疾病的早期筛查、鉴别诊断、疾病进展预测及药物疗效监测，具有高灵敏度、高特异性和微创检测的优势。
Nº publicación: CN122631877A 25/08/2026
Solicitante:
宁波大学
Resumen de: CN122631877A
本发明公开了一种基于磁性SERS编码探针与单线捕获的多重生物标志物同步检测方法及系统，采用Aβ40磁性SERS编码探针、Aβ42磁性SERS编码探针和p‑tau‑181磁性SERS编码探针构成的混合探针与待测血液样本共同孵育，配合磁富集与分离，将LFIA试纸条的检测限降至fg/mL级别；Aβ40磁性SERS编码探针、Aβ42磁性SERS编码探针和p‑tau‑181磁性SERS编码探针标记的三种不同拉曼信号分子特征拉曼峰彼此无重叠，LFIA试纸条的T线同时包被三种特异性捕获抗体，一次层析、一次光谱采集即可同步定量检测三种标志物；优点是能够同时实现血液样本中的三种生物标志物的高灵敏度、高特异性、快速、同步定量检测。
BOPI
Sede Electrónica
